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Clinician–researchers and custodians of
scarce resources: a qualitative study of
health professionals’ views on barriers to
the involvement of teenagers and young
adults in cancer trials
Ruth I. Hart1* , Nina Hallowell2, Jeni Harden1, Angela B. Jesudason3† and Julia Lawton1†
Abstract
Background: Equipoise and role conflict have been previously identified as important factors in professionals’
engagement with trials, inducing behaviours which can impact on recruitment. We explored these phenomena as
potential explanations for the low levels of involvement of teenagers and young adults (TYA) with cancer in clinical
trials in oncology.
Methods: We report findings from interviews with 30 purposively sampled direct-care professionals involved in
delivering cancer care and/or facilitating clinical trials in Scotland. We undertook qualitative descriptive analysis,
focussed on identifying key issues and themes.
Results: Interviewees largely identified as clinician–researchers and portrayed oncology as a specialty in which
research was integral to care. They saw their primary responsibility as ensuring patients received the best treatment,
but asserted that, in general, trials provided a vehicle for optimal care. Role conflict in its traditional form was rarely
evident; however, other tensions were manifest. Professionals found the significant time costs of delivering trials
difficult to reconcile with the increasing pressures on clinical services. They felt a responsibility to make prudent
choices about the trials with which to engage. Guided by utilitarian principles, these choices were oriented towards
benefiting the largest number of patients. This favoured trials in high volume diseases; as TYA tend to have rarer
forms of cancer, professionals’ support for—and TYA’s access to—relevant trials was, by default, more limited.
Conclusions: Neither lack of individual equipoise nor experiences of traditional forms of role conflict accounted for
the low levels of involvement of TYA with cancer in clinical trials. However, prominent tensions around the
management of scarce resources provided an alternative explanation for TYA’s limited access to cancer trials. The
prevailing approach to decision-making about whether and which trials to support was recognised as contributing
to inequalities in access and care. Professionals’ choices, however, were made in the context of scarcity, and
structured by incentives and sanctions understood by them as signalling governmental priorities. A franker
discussion of the extent and distribution of the costs and benefits of trials work is needed, for change to be
achieved.
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Background
Clinical trials have played a definitive role in medical
progress, particularly in the field of cancer care [1]. Im-
portant patient outcomes, including survival, have im-
proved significantly in that specialty since the expansion
of trial activity in the mid-twentieth century [2]. How-
ever, not all cancer patients have had the same level of
involvement in trials, and patient populations with lower
levels of trial involvement have seen more modest im-
provements in outcomes. Teenagers and young adults
(TYA) with cancer are one such group; levels of trial
participation and improvements in outcomes for this
group contrast particularly dramatically with those
achieved in paediatric oncology, where trial participation
levels have been high [3–5].
Whilst clinical trials are powerful tools for advancing
knowledge and patient care, their successful delivery is
difficult, with recruitment challenges affecting timely
completion of a significant proportion of studies [6, 7].
A growing body of research has sought to understand
the barriers and facilitators to recruiting into clinical tri-
als, initially by exploring patients’ views and experiences
[8–13]. More recently, researchers have investigated the
perspectives of health professionals charged with recruit-
ing, consenting, and retaining patient participants [14–
17]. Two distinct but related explanatory concepts have
been suggested as affecting professional recruitment
practices and trial outcomes: the existence (or not) of
equipoise and experiences of role conflict.
Clinical equipoise [18] is considered a fundamental
ethical requirement of any trial involving random alloca-
tion. In essence, being ‘in equipoise’ means being in a
state of uncertainty about the relative scientific or clin-
ical merits of the different arms of a clinical trial. When
there is uncertainty about which treatment is preferable,
then conducting a trial is justified. Distinctions have,
however, been drawn between clinical and individual
equipoise (uncertainty), and these may not be fully
aligned [15, 19]. So, while health professionals may agree
that clinical equipoise exists, i.e. recognise that a lack of
consensus exists amongst medical experts, equipoise at
the individual level is often less stable. Individual
healthcare professionals may believe that one form of
treatment is generally superior, or that specific
(groups of) patients would benefit more from one
treatment than another. Disturbances in individual
equipoise may lead professionals to undertake select-
ive or biased recruitment, such as not broaching trial
participation with certain groups or individuals, or
introducing a trial in a way that prompts patients to
decline involvement [14, 19–21].
Underpinning these behaviours is a concern that par-
ticipation would not be in patients’ best interests. The
care obligations at the heart of the clinician-patient
relationship are deeply felt, and whilst clinical equipoise
may provide ethical justification for allocation of patients
to treatment according to a trial protocol, individual un-
certainty will almost inevitably leave clinicians feeling
conflicted. Broader tensions between goals and responsi-
bilities relating on the one hand to research or scientific
endeavours, most particularly clinical trials, and on the
other to the care of (individual) patients, have been con-
ceptualised as manifestations of role conflict [22–24].
Role conflict arises because clinical trials are driven by
hypotheses, which are operationalised in protocols that
determine the care a patient receives (in lieu of assess-
ments of patients’ individual circumstances, preferences
or needs). This can lead professionals to question
whether the interests of their patients might not be bet-
ter served by more tailored care, albeit that the provision
of such care may not be consistent with the priorities of
the trial. This sort of conflict has been identified as gen-
erating significant discomfort for health professionals in
a range of positions and specialisms. As with lack of
equipoise, where responsibilities to individual patients
are deemed to conflict with and override those due to
research endeavours, behaviours which may impact
negatively upon recruitment can be triggered [20, 25,
26].
As part of a wider study of barriers (and facilitators) to
TYA’s involvement in cancer trials, we interviewed
health professionals involved in delivering cancer care
and/or facilitating clinical trials. In keeping with the lit-
erature, we anticipated that a lack of equipoise (individ-
ual uncertainty) and/or role conflict might offer
explanatory vehicles for the low levels of involvement of
TYA in cancer trials. Our findings did not support this.
In particular, they (our findings) did not show role con-
flict, as currently understood and employed in the litera-
ture, to account for limited trial participation by TYA.
However, as we explain below, they revealed other new
and highly significant tensions, with ultimately similar
consequences for TYA’s involvement in trials.
Methods
We outline our methods—and findings—broadly in ac-
cordance with the consolidated criteria for reporting
qualitative studies (COREQ) [27]. The use of such
checklists is advocated in and by many clinical and sci-
entific journals [28], although it has been problematized
by some prominent researchers [29].
Design and theoretical framework
We undertook a qualitative study, involving one-off
semi-structured interviews with direct care and other
professionals, patients and family caregivers (data from
non-care professionals, patient and caregiver interviews
will be reported separately in due course). The study was
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characterised by an emergent, inductive design, purpos-
ive sampling and an iterative approach to data collection
and analysis [30]. This iterative approach enabled us to
revise our sampling strategy and interview topics, and to
capture and unpack emerging issues (including some
unanticipated when the study began). Our work was
lightly informed by Normalization Process Theory
(NPT), a middle-range theory offering an explanatory
framework for ‘how complex practices… are made work-
able… in context-dependent ways’ (p.536) [31]. Amongst
other things, NPT sensitised us to the potential for dif-
fering institutional contexts to shape and produce vari-
ation in interviewees’ experiences and perspectives, and
the need to allow for this possibility in our sampling and
interview questions.
Setting
We conducted our study in Scotland. Health is a de-
volved matter, with legislation relevant to the National
Health Service (NHS) in Scotland made by the Scottish
Parliament. NHS Scotland is legally and financially inde-
pendent from NHS England and has a distinct organisa-
tional framework. Fourteen regional ‘Health Boards’
plan, commission and deliver services, in line with the
Scottish Government’s priorities. Major and specialist fa-
cilities are concentrated in the four largest health boards,
although more than 20 hospitals in Scotland provide
cancer care. Research infrastructure is provided by NHS
Research Scotland (NRS), which takes its strategic direc-
tion from the Chief Scientist Office (CSO), an arm of
the Scottish Government (and the funder of this re-
search), and the four largest health boards.
Participants and recruitment
Our approach to sampling was purposive and focussed
on construction of a sample reflecting the diversity of
relevant experiences and perspectives. Hence, we set out
to recruit medical and nursing staff from different sub-
specialties, types of service, hospitals and health boards
(for example, small, large, rural, urban, with and without
specialist TYA services/facilities). In light of the issues
emerging in the first phase of the interviews, which re-
lated substantially to what might be termed structural
factors (obstacles to the timely approval and set-up of
relevant trials), we later sought to recruit professionals
whose roles gave them particular insight into those mat-
ters. Initially, potential research participants were identi-
fied by clinical members of the research team. As
sampling progressed, help to identify professionals with
particular characteristics and/or experiences was sought
from advisory group members and other clinical col-
leagues. We also invited interviewees to suggest col-
leagues with whom we might usefully speak.
Interviewees were not asked to introduce us to their
colleagues and were not informed whether their sugges-
tions were followed up.
Approaches to potential interviewees were made in
writing, either by the Chief Investigator (AJ) or the pro-
ject researcher (RH), and were followed up by the latter.
All potential interviewees were given detailed participant
information sheets and invited to opt-in by replying dir-
ectly to the project researcher. Approximately half of
those approached agreed to take part. Where reasons
were given for declining participation, these typically re-
lated to pressures of work and/or the small number of
TYA patients seen. We discontinued recruitment once
the team was in agreement that sampling ambitions had
been satisfied and data saturation had been reached (i.e.
the data set included an appropriate range of partici-
pants and perspectives, and additional interviews were
no longer generating new issues or themes).
Data collection
Data was collected between December 2017 and August
2018. Interviewees were given the option of either a
face-to-face or telephone interview, with the former (16/
30) typically taking place in the interviewee’s own office
or a private meeting room. These were conducted by the
project researcher (RH), a social scientist with prior ex-
perience of undertaking qualitative health research in
haemato-oncology and other clinical areas.
Interviews were semi-structured, loosely following a
topic guide outlined in Table 1. This was informed by a
review of the literature, the expertise of the research team,
and input from advisory group members. In line with
study’s inductive and iterative approach, the topic guide
was revised over the course of the study in light of emer-
ging findings. Questions were modified in situ to take ac-
count of interviewees’ varying roles, experiences and
perspectives. As such, the guide should be considered pre-
cisely that, and not as a script. Interviews typically lasted
45–60min. All were audio-recorded and then transcribed
verbatim. After anonymization had been fully confirmed,
transcripts were imported into the specialist data manage-
ment software, NVivo (Version) 11 (QSR International
Pty Ltd., Doncaster, Victoria, Australia).
Data analysis
We undertook qualitative descriptive analysis, with a
focus on producing rich, ‘minimally theorized’ descrip-
tions of views and experiences [30, 32]. After initial fa-
miliarisation with the transcripts, which involved close
reading and line-by-line coding, two members of the
research team (RH and JL) undertook more focussed
coding and ‘constant comparison’ [33]. Having under-
taken independent analyses of the data, these re-
searchers met to discuss and reflect upon their
interpretations. The two analyses were very similar; hence,
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consensus on the coding frame for subsequent work was
easily reached. The final stage of the analysis involved a
further round of coding and constant comparison, with
the project researcher (RH) systematically comparing,
sorting and associating data and codes, until patterns, sub-
tle variations and exceptions became clear. Summaries, di-
agrams and analytical reports enabled the analysis and
gave other members of the team access to the data and
the analytical logic.
Results
We interviewed 30 direct care professionals whose
role(s) involved delivering cancer care and/or facilitating
clinical trials in Scotland. Participant characteristics are
detailed further in Table 2.
In the sections that follow, we report how (1) these
professionals largely identified as clinician–researchers
and offered little evidence of experiencing role conflict
in its traditional form, but (2) other powerful tensions
had emerged around the use of scarce resources. Quotes
are attributed to participants who are distinguished
using unique alphanumeric codes, the initial letters of
which provide information on their role: DC-C/N/O
(Direct Care-Consultant/Nursing/Other). No relevant
differences in perspective by role/staff group emerged.
Identifying as clinician–researchers
Interviewees with direct care roles strongly identified as
clinician–researchers, with accounts emphasizing the
close integration between research and care in contem-
porary oncology. They portrayed involvement in re-
search, particularly clinical trials, as an integral part of
their work; something which was the norm, rather than
the exception, for professionals within their specialism:
‘it’s part of core work… you can’t do oncology without
doing research, it’s just… part of our job… just about
every oncologist is involved in clinical trials… and if
you’re not, you’ve got the question, why not?’ (DC-C-11).
‘in oncology, (research) is integral to clinical care…
that’s what makes it such an interesting speciality,
everyone’s involved… (and) it’s very integrated into
clinical practice.’ (DC-C-12).
Clinicians described being introduced to clinical tri-
als work early in their medical career and talked of
taking on more responsibilities for trials work as they
gained experience and status in oncology. Current on-
cology trainees, they said, were being prepared to take
on similar responsibilities in the future. For example,
as part of the medical oncology curriculum, trainees
were all expected to undertake ‘GCP’ (Introduction to
Good Clinical Practice) training, and to be involved
in recruiting patients to trials, as well as providing
follow-up care.
Some nursing interviewees were in research/trials
nurse roles at the time of interview; others were not, but
had held such posts in the past. Several recalled involve-
ment, as staff nurses, in the care of cancer patients
treated through clinical trials. This, they said, had given
them too a strong sense of the importance of trials work
and its contribution to improving cancer care:
‘you can see the development of drugs over the course
of the years… you can actually see that with, you
know, with your own eyes… that’s motivational, you
Table 1 Interview topic guide
About the interviewee:
Role/responsibilities, including clinical and other interests
Contact with TYA patients
Experiences of providing care to TYA
If/how providing care to older adults (or children) is different
Involvement with trials:
Understanding of the term
Experience of trials work
Reasons for doing trials
Views on costs and benefits of trials (to current and future patients,
professionals, and organisations)
Decision-making about whether to open any specific trial locally
Processes for opening a trial locally
Barriers and facilitators to timely opening of trials
Scope for improving processes
Recruiting TYA (and other) patients to trials open locally
Experience of recruiting TYA (and other) patients
Processes for identifying eligible patients
Deciding whether or not to approach individual patients
Who/what is involved in recruitment
Issues, concerns, and/or challenges specific to TYA (in general and/or sub-
groups)
Referring TYA (and other) patients to trials open elsewhere
Experience of referring TYA (and other) patients
Processes for identifying eligible patients
Deciding whether or not to approach individual patients
Who/what is involved in referral
Issues, concerns and/or challenges associated with referral to trials open
elsewhere
Issues, concerns and/or challenges specific to referring TYA to trials open
elsewhere
Increasing TYA participation in trials
Explanations for variation (in levels of participation) between services and sub-
specialisms
How to promote trial participation by this age group
Other issues or comments
Changes in context and/or trials
Emergent issues
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know, to being positive about trials, and taking part in
them.’ (DC-N-10).
Both clinicians’ and nurses’ accounts gave a strong im-
pression of a trial culture, underpinned by a commit-
ment to evidence-based medicine and with a focus on
improvement, patient safety and the provision of the
highest quality of care:
‘if we don’t do clinical trials, we will make decisions…
not based on the best evidence… we have to do
clinical trials to actually improve outcomes, but also
to protect patients from drugs or interventions that
might actually not be as effective as what’s already
available.’ (DC-C-26).
Significantly, clinical trials were viewed not only as de-
livering benefits for future patients, but also as profiting
current patients. Interviewees largely shared the opinion
that research-active organisations achieved better results
for patients (generally) and that patients who took part
in trials had superior outcomes to those who did not. In-
terviewees acknowledged some uncertainty as to why pa-
tients in centres that delivered trials did better. They
Table 2 Participant characteristics
Interviewees with direct care responsibilities 30
Type of healthcare professional Consultant 23
Nursing 4
Other 3
Consultants’ specialisms Clinical oncology 7
Medical oncology 6
Haematology 6
Paediatric medicine 3
Surgery 1
Consultants’ site/sub-specialisms* Haematological malignancies 5
Gastro-intestinal cancers 4
CNS/Neurological 3
Genito-urinary cancers 3
Breast cancer 2
Gynaecological cancers 2
Head, neck & thyroid cancers 2
Sarcomas 2
Paediatric oncology 2
Lung cancer 1
Melanoma 1
MCUP 1
If also had research development or support responsibilities No 25
Yes 5
Type of responsibilities Senior role in a CTU or CRF 3
Specialist trial support** 2
Board to which primarily affiliated NHS Lothian 11
NHS Greater Glasgow & Clyde 8
NHS Highland 4
NHS Tayside 3
NHS Grampian 2
NHS Fife 1
Other primary affiliation*** 1
* Several consultants worked in more than one sub-specialism; therefore, these numbers do not sum to 23
** With regard to pharmaceutical or radiographic components
*** Interviewee primarily affiliated to an institution outside Scotland
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offered explanations concerning, inter alia, the culture or
outlook developed by involvement in trials, and the
value of external scrutiny of practice:
‘Trials make people think… (be) adaptable and willing
to change for the better… that’s a culture that…
taking part in clinical trials develops, or encourages.’
(DC-N-10).
‘we also know that… being part of research is quite
good from a quality control point of view… your
patient care… is being compared by the trials
monitoring committee, it’s almost like… intellectual
peer review… of practice.’ (DC-C-16).
A significant proportion of interviewees referred to
‘evidence’ suggesting that patients enrolled in trials had
better outcomes. Again, interviewees acknowledged it
was not yet entirely clear why trial-enrolled patients did
better. They stressed that new treatments or new ways
of administering treatment did not always outperform
standard care and cited ‘research’ showing that control
arm patients also tended to have better outcomes than
non-enrolled peers:
‘there’s… evidence… that patients who participate in
trials do better, irrespective of whether they’ve got the
trial treatment.’ (DC-C-13).
Interviewees suggested that the explanation was prob-
ably ‘multi-factorial’ (DC-C-11), identifying a series of
factors or mechanisms for what is sometimes referred to
in the literature as ‘the trial effect’ [34]. These related
largely to care practices—careful observation of a treat-
ment protocol, scrupulous monitoring, and diligent
recording:
‘there’s quite a lot of evidence to say that patients in
clinical trials get better clinical care, just ‘cause they
are seen more frequently, and so you’re much more
likely to pick up on symptoms, and problems, at an
earlier stage. So for individuals, it’s always
important to stress that the benefit’s not necessarily
from the drug, or the technique, because we don’t
know yet if that’s going to make any difference, but
we know that generally speaking, because of the
more intensive care provided for people in trials
for collecting all the data, that translates into sort
of better clinical care.’ (DC-C-5).
Whatever the explanation, treatment through a trial
was, in principle, viewed as giving patients access to the
best possible care. As such, our interviewees gave little
impression of being conflicted in the performance of
their clinical care and research responsibilities; in con-
trast, they saw trials as a vehicle through which they
could offer their patients optimal clinical care.
Accounting further for the apparent lack of conflict
between care and research, interviewees reflected on the
characteristics of the trials with which they were in-
volved, and the distinctive nature of those of most rele-
vance to TYA patients. Although some direct care
interviewees reported involvement in early phase trials,
most interviewees and accounts focussed on ‘Phase 3’
(large-scale, randomised) trials of first-line care. These
are the sorts of trials involving the largest number of pa-
tients and, archetypally, compare two quite distinct
drugs, procedures or technologies, one of which is new.
The trials described by our interviewees appeared not-
able for their complexity, comparing differences in pro-
tocols which could involve multiple treatment
modalities. Interviewees acknowledged that, in principle,
such a trial might still expose patients to a new agent
that was inferior to current care. However, several inter-
viewees took pains to note that ‘new’ did not mean en-
tirely unknown, one commenting as follows:
‘in (this sort of) trial you feel you’ve come far down
the road enough, for, you know, the “new” drug not to
be a worse drug. It (may) not be better, but there are
reasonable data to say… it shouldn’t be worse.’ (DC-
C-7).
They stressed that patient safety was the prime consid-
eration in the design of trials and that all were very care-
fully scrutinised before initiation. Though laborious to
navigate, regulatory and review processes functioned
both to minimise harm and to reassure clinicians that
they were not exposing their patients to inappropriate
risks:
‘Our process for taking on trials, and the way that our
consultants work… we’re quite confident that we’re
not offering things to people that wouldn’t be good
for them.’ (DC-N-10).
Moreover, interviewees described trials in the disease
areas of most relevance to TYA patients (for example,
sarcomas, brain tumours, and acute leukaemia) as com-
monly exploring different ways of using familiar treat-
ments, sometimes using ‘different treatment approaches
using the same drug’ (DC-C-9), rather than investigating
the effects of new ones:
‘Some of the studies… are actually looking at what
other medicines we can take out, or lower the dose of,
to cut down on side effects, so… trials are not
necessarily about new treatment.’ (DC-C-17).
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‘Trials (can) offer an opportunity to access medicines
that we otherwise wouldn’t be able to… (But) a lot of
our trials… are not like that though… a lot of our
trials involve making minor modifications to…
standard treatments.’ (DC-O-24).
As the quotes above suggest, interviewees portrayed
these trials, which seldom had commercial funding, as
often looking at quite subtle modifications to care, for
example, making adjustments to treatment combina-
tions, order, dosage and/or frequencies. Interviewees
talked of attending to ‘the finer details of the treat-
ment… trying to clarify aspects of that treatment’ (DC-
C-3). One explained how they proceeded:
‘building on what our, our gold standard, or our best
available therapy is, and we’re trying to tweak the
treatment slightly to improve outcomes, or add in a
new treatment, or change the doses, or change the
scheduling of it… (to) further improve the
treatment… to improve the outcomes.’ (DC-C-17).
Priorities varied between disease areas / tumour types,
but outcomes of interest included both survival and
(short and longer-term) toxicities. The latter was viewed
as of particular significance to TYA patients:
‘in both haematology and breast cancer… we’ve got
such good outcomes really, that it’s all about trying
now to look at, how little do we need to do to get the
same outcomes, to keep the quality of life? So there’s
quite a lot of work about how much can we pull
back… and still achieve the same results… The
younger population, those people are hopefully going
to be cured, and then live till they’re 80, so you don’t
want them to live with the side effects of the
chemotherapy or radiotherapy’ (DC-C-15).
Such trials were framed as exposing TYA patients to
worthwhile benefits and quite limited risks:
‘I’m fairly enthusiastic about putting my acute
leukaemia patients in trials… because… they get a
fairly good deal in these trials and the risk-benefits…
are pretty good.’ (DC-C-7).
Furthermore, the nature of these trials meant that the
superiority of any particular arm was exceedingly diffi-
cult to pre-judge:
‘the basis for the trial is that we don’t know which
one’s going to be better, or better tolerated… that’s
the nature of a Phase 3 trial, we can’t run it unless we
think there’s genuine uncertainly about which one is
best. (And in these trials) that difference is much less
apparent to anybody, even (those) running the trial.
It’s less clear what, whether you would have been
better off, if you had the other bit.’ (DC-C-3).
New tensions emerging
Whilst interviewees expressed a deep commitment to re-
search and saw it as an integral part of their responsibil-
ities, most were employed primarily to deliver clinical
services:
‘most people in, in oncology are NHS doctors… who
believe in research, who do research, but whose first
commitment is to the NHS service.’ (DC-C-11).
‘although they are interested in research, and
involved, and want to... be involved, they have a
clinical workload… real patients, and real people, that
have to be dealt with.’ (DC-O-30).
Many talked of growing pressures on core services:
clinician and nursing time, pharmacy, radiology/radio-
therapy services and laboratory staff and facilities. Cer-
tain fields (solid tumour oncology), services (radiology),
and health boards (rural) were suggested as facing par-
ticular or persistent challenges:
‘in adult solid tumour oncology, we’ve had a severe
shortage of staff… across the UK. So workload has
been a huge issue…’ (DC-C-25).
Interviewees from one health board reported long-
standing difficulties with clinical staffing, with vacant
consultant posts leaving them heavily reliant upon lo-
cums. Meanwhile, colleagues in another health board de-
scribed their pharmacy and radiology services as
struggling to deliver standard care. They relied on their
larger neighbours for some work related to routine clin-
ical services:
‘we… use (City) labs for a lot of things anyway… that’s
standard… if there’s extra tests… that can be an issue.’
(DC-N-22).
These pressures made the costs associated with under-
taking trials, in particular staff time, increasingly hard to
absorb. Although trials were framed by some inter-
viewees as a potentially useful source of income, they
were more frequently construed as drawing critical re-
sources away from routine care. This may in part be re-
flective of the source and levels of funding for the TYA-
relevant trials around which conversations revolved.
All current and recent trials of clear relevance to TYA
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with cancer which featured in interviews were non-
commercial, i.e. funded by charities or through (Euro-
pean) grant programmes.
Notwithstanding their commitment to participating in
such research, many interviewees talked at length of the
significant monetary and other (e.g. in-kind) costs asso-
ciated with establishing, opening and maintaining these
trials: ‘trials are demanding in time, they’re demanding
in resource…’ (DC-C-16). They drew attention to the
substantial time costs associated with both opening and
delivering a trial. These costs included trial administra-
tion, recruitment, delivery of complex trial interventions,
data collection and reporting.
The demands associated with trial administration re-
ceived particular attention and were framed both as sig-
nificant and expanding. An experienced clinician
remarked how, over their professional lifetime, they had
‘ballooned, absolutely ballooned’ (DC-C-25). Comments
were also made that whilst non-commercial trials used
to be more straightforward to administer, they were now
expected to meet the same regulatory and reporting re-
quirements as commercial trials—but without equivalent
resources and infrastructure. Opening a trial was por-
trayed as extremely laborious and, critically, due to the
requirement to maintain and update documentation to
reflect (increasingly frequent) amendments, the ongoing
demands on staff time were also considerable:
‘Seven or eight years ago, you would maybe see one or
two protocol amendments in the lifetime of a study.
Now you’re seeing two or three a year, it’s out of
control, there’s more protocol amendments than
patients on half our studies. And staying on top of
that is extremely difficult.’ (DC-O-9).
Interviewees emphasised that, in large part, these ad-
ministrative demands bore no relationship to the scale
of recruitment to the trial. Due to broadly equivalent
costs of activation, set-up and maintenance, trials where
recruitment might be expected to be limited (often the
case with those in disease areas relevant to TYA) could
prove as much a drain on resources as those with much
higher levels of recruitment:
‘if we do a trial where we’re going to recruit 10
patients, then obviously the amount of work that I
have to do as a PI… and some of the nurses have to
do – in terms of bureaucracy – is actually pretty
much the same as if we were to do a trial where we
might only recruit one.’ (DC-C-25).
Hence, in this context of high demand and scarce re-
sources, accounts suggest that trials were in competition
not only with clinical services, but also with each other.
Interviewees drew attention to the ‘finite’ nature of re-
sources, the ‘opportunity cost’ of trials work, and the
consequential requirement to make prudent choices
about which trials to engage with and fight for support
for:
‘as a department, we’ve got limited research resource,
so we… focus on trials… (with) a chance of benefiting
our patients. Focus our nursing and data management
resource into that.’ (DC-C-11).
Pressed to explain further how decisions were made
whether to engage with (i.e. open) a particular trial or
not, interviewees talked about assessing if a trial was
‘worthwhile’. This appeared to mean a range of different
things, prominent amongst which was recruitment
potential:
‘it’s about numbers, how many people do you need to
get into a trial in order to make the trial… worth the
resource…?’ (DC-C-3).
Professionals appeared to evaluate trial opportunities
according to the principles of utilitarianism, which, at its
simplest, is an economic philosophy oriented towards
achieving the greatest good for the greatest number of
people. Interviewees acknowledged that the prevailing
value system privileged high volume diseases (for ex-
ample, breast and prostate cancer). As one interviewee
put it, ‘the big tumour types… dominate’ (DC-C-11). Ac-
counts suggest that the system of rewards and penalties
for trials work established by the Scottish Government
(CSO) had encouraged and embedded such an approach.
Its use of recruitment figures as the central metric
incentivised trials in those centres, disease types, sub-
types and phases where there was greatest potential to
recruit:
‘Not to beat around the bush, we get very little
money, until we recruit patients. You know, most of
the incentivisation… bean-counting, is related to the
numbers of recruits, not to the numbers of… studies.
And so, you know, those are resources which, we’re
putting in, where we may get nothing back, and would
frankly be better directed to something where we’re
gonna get something back.’ (DC-C-28).
Some interviewees questioned the rationale of the con-
temporary rewards system, musing that:
‘number of recruits to studies… that’s a slightly lazy
way of trying to appreciate the quality and quantity of
patient benefits… if you run a study on relatively few
patients, but actually that’s a novel, good intervention,
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that would be a great benefit… the health impact may
be… more significant that a study that runs on 100
patients which provides relatively minor, additional
health benefits… Yet the 100-patient (study) would
win, in the eyes of the Government.’ (DC-C-27).
Ultimately, and notwithstanding ambitions to have tri-
als available for as many different patient groups as pos-
sible, there was widespread recognition that, in reality,
only a minority of patients aged 16+ had access to care
through a trial. One interviewee (DC-C-20) put it very
bluntly: ‘for the majority of patients, there isn’t a trial.’
Significantly, however, the prevailing logic and rewards
metric led to patterned inequalities in access to trials,
powerfully dis-incentivising the opening of trials relating
to rarer cancers such as those with which TYA typically
presented:
‘(be)cause the numbers are small… staff are kind of
dis-incentivised… A lot of people just say, I just can’t
be bothered with that if I’m only gonna recruit, you
know, one patient in six months or something, why
the hell do I wanna do that? I’ve got other things to
do.’ (DC-C-25).
Some interviewees highlighted a wider lack of trials in
rare tumours, framing pharmaceutical companies as hav-
ing limited interest in developing and trialling new treat-
ments for such diseases (as the returns were likely to be
modest and only distantly realised). Others questioned
the extent to which smaller centres, outside London,
were given an opportunity to participate where such tri-
als were established. Many, however, explicitly acknowl-
edged the role—and consequences—of local decision-
making:
‘There is a national trial for rhabdos, but we haven’t
opened it in, the adult site, because it’s a very
complicated trial, and we would probably only get one
patient every two or three years… ‘cause it only goes
up to (age) 21, I think’ (DC-C-3).
‘there are some trials for very rare cancers… quite a
few that are relevant to this group (TYA), where we
have had to just make the decision, we don’t have
enough resources to open this trial that we may
recruit one, or zero patients (to) over the lifetime of
the trial… that’s a big problem… for this group of
patients.’ (DC-C-18).
It seems TYA patients might not be deprived of trial
opportunities by their age per se, but by their tendency
to present with tumours uncommon in the wider adult
population:
‘we’ve got about 160 trials open… (but) there’s
probably about half a dozen… which would include
diseases which were relevant (to TYA).’ (DC-C-28).
Discussion
A key finding of our research is that interviewees identi-
fied strongly as clinician–researchers and portrayed on-
cology as a specialty in which research was integral to
care. Examples of role conflict in its traditional form
[22–24] were largely absent from our data. However,
there was evidence that new and significant tensions had
emerged, which offered a powerful alternative explan-
ation for the low levels of involvement of TYA with can-
cer in clinical trials in oncology. Specifically, our data
suggest that, inasmuch as research was felt to conflict
with care, it was in its potential to consume increasingly
scarce and precious clinical resources. Our data reveal
an acute appreciation of resource scarcity and a sense of
obligation amongst professionals to make deeply prag-
matic choices about those trials in which to invest their
time. Guided by utilitarian principles, these choices were
oriented towards benefiting the largest number of pa-
tients. This favoured trials in high volume diseases; as
TYA tend to have rarer forms of cancer, their access to
trials was, by default, limited. Interviewees recognised
that the choices they made as professionals about which
trials to support had very concrete repercussions for
equality of access—and arguably care. TYA and other
patients presenting with rare cancers (and indeed other
rare diseases) were acknowledged as being systematically
disadvantaged.
These findings do not fit entirely easily with the exist-
ing literature. Traditionally, the roles of clinician and re-
searcher have been understood to be fundamentally
distinct and inherently conflicting. Attention has been
and continues to be drawn to differences in the goals,
practices, responsibilities, obligations, risks and ethical
frameworks for research and care [20, 22–24, 26]. The
form and consequences of these role conflicts (for clini-
cians, patients and, to a lesser extent, researchers) have
been relatively well documented, including in studies fo-
cussed on the conduct of clinical trials [14, 16, 35]. Role
conflict has been found to have implications for both re-
cruitment and trial delivery; for example, previous work
has shown that clinicians will not follow a trial protocol
if they are concerned that it will deprive their patients of
the best clinical care [36].
That said, recent years have seen the publication of a
growing body of work which challenges the conceptual-
isation of care and research as unerringly distinct and
conflicting. That work suggests a more permeable
boundary between research and care, at least in some
technical specialities [37–39]. Keating and Cambrosio
Hart et al. Trials           (2020) 21:67 Page 9 of 13
[1] and Cambrosio et al. [40] have argued that, in the
field of oncology, the practices of standard care and par-
ticipation in trials have become closely intertwined. Our
own work very much supports that claim. Whilst inter-
viewees were clearly cognisant of the clinical essence of
their identity [20] and saw their primary responsibility as
ensuring patients received the best clinical care, they
also viewed trials, in general, as a vehicle for providing
optimal care. This finding is in line with expert opinion
[41] and other research [37], which similarly has found
clinicians to perceive trial enrolment as a means to pro-
vide their patients with first-class care.
Interestingly, our data showed professionals to be
overwhelmingly in (individual) equipoise. We surmise
that the nature of TYA-relevant trials may be significant
in this. Our data suggest that whilst TYA-relevant trials
may involve new treatments, they frequently compare
relatively similar regimens, involving differential delivery
of familiar treatments. Where differences between treat-
ment arms are subtle, it would seem less likely that pro-
fessionals might hold strong beliefs regarding the
likelihood of particular patients or patient groups bene-
fiting more from one treatment (arm) than another. Ar-
guably, in such cases, the potential for individual
uncertainty about involving one’s patients in such a
trial—and all the concerns and conflicts arising from or
fuelled by this—would be reduced.
Although traditional forms of role conflict were largely
absent from our data, powerful tensions, or conflicts, were
prominent in relation to resource management. Highlight-
ing a backdrop of fiscal crisis, or at least constraint, our in-
terviewees portrayed themselves as having secondary, but
nonetheless significant, roles as custodians of scarce re-
sources. They indicated acute awareness of the finite na-
ture of NHS resources and a sense of duty to use these to
maximum effect. Many talked at some length of their
struggles to reconcile the significant costs associated with
involvement in trials with the increasing pressures on their
clinical service. Other authors have documented the con-
siderable time and other costs associated with involve-
ment in trials [42–44], with some citing financial
constraints as a significant barrier to involvement in (non-
commercial) trials [37]. More than a decade ago Snowden
et al. [45] argued that financial considerations shaped all
aspects of trial work and deserved far closer scrutiny than
they had received. Our study helps to fill important gaps
in understanding of the actual—and perceived—econom-
ics of trials research, and how these mould professionals’
decisions and behaviours.
Our data highlight the significant and growing chal-
lenges for healthcare professionals of being involved in re-
search—a product of the burgeoning pressure on clinical
services and the increasing cost and complexity of clinical
trials. These challenges meant that, notwithstanding a
deep commitment to trials, only a minority of patients
(aged 16+) could be offered treatment through a trial.
Scholars working in other jurisdictions have similarly
noted that, whilst central to the specialty, in practice, rela-
tively few (adult) oncology patients take part in trials [1,
46]. Our interviewees emphasized their responsibility to
make parsimonious choices between trial and other activ-
ities and portrayed trials as being in competition both with
clinical services and each other. They described making
deeply pragmatic decisions about trial engagement, with
decisions being oriented towards containing costs and
maximising returns. These appeared to follow a crudely
utilitarian logic where benefits are calculated according to
the number of potential recruits. We see parallels here
with Lipsky’s depiction of the classic ‘street-level bureau-
cracy’, where demands on professionals always exceed the
resources available, leading to the development of routines
and rationing mechanisms enabling the maximal utilisa-
tion of resources whilst maintaining ‘a conception of…
performance relatively consistent with ideal conceptions
of the job’ (p.151) [47].
The current system of rewards and penalties for trial
activity appeared to reinforce a focus on ‘high volume’
diseases and to explicitly dis-incentivise more complex
or uncertain (in terms of recruitment) trials work.
Again, this finding is consistent with Lipsky [47], who
argues that discretionary behaviours may ‘add up’ to
policy, but emerge in and from a context which not
only structures the choices available, but also provides
incentives and sanctions which, in turn, are correctly
understood by workers as signalling leadership/man-
agement priorities. Such incentivisation schemes are
both widespread in the NHS and widely problematized
(see for example the debate around the Quality and
Outcomes Framework (QOF) [48]). Professionals inter-
viewed for this study recognised that their choices pro-
duced patterns—and, as a consequence, inequalities—in
access to trials. Interviewees acknowledged that patient
groups characterised by small numbers, such as TYA—
who tend to present with rare types of cancer—and/or
are served by smaller treatment centres, were amongst
those most consistently disadvantaged. Differential
treatment of different patient groups was, in line with
Lipsky, rationalised as serving “the best interest of the
greatest number’ (p.112) [47]. However, while choices
were rationalised, their potential to explain and com-
pound disparities in health outcomes acted as a source
of some discomfort to interviewees.
Although the consequences of this new form of role
conflict may be similar to those of more traditional
forms, the causes are quite different. As such, proposed
solutions to traditional forms of role conflict, such as,
for example, more or better training on the concepts
central to trials and how best to communicate these to
Hart et al. Trials           (2020) 21:67 Page 10 of 13
patients [49], would appear to have uncertain relevance.
Guidance not on the mechanics of recruitment but in-
stead on how to balance competing obligations and
undertake ‘boundary work’ [50] might be more valuable.
Critically, more than a decade ago, Raftery et al. [51]
called for better understanding of the organisational and
resource aspects of trials and how these impact on re-
search involvement and recruitment. This need does not
as yet appear to have been fully met. Recognition of the
increasing complexity and cost to health care institutions
of hosting trials [41] would seem to us to be a necessary
condition of change. Changes to current systems of re-
wards and penalties for trial activity may also be needed,
if health professionals are to be encouraged to make dif-
ferent choices.
Strengths and limitations
Qualitative research can improve understanding of the
views, behaviours and decisions of health professionals
(and their patients) [28, 52, 53]. It can also prompt the
problematization and refinement of concepts and ideas,
as demonstrated above. Critiques often concern general-
isability; although such generalisability is rarely the goal
of qualitative research, it is of interest whether, and with
what caveats, findings have wider application. The na-
ture of study samples is key to this. As noted in our
Methods, sampling was purposive and continued until
we were confident ‘saturation’ was achieved. Inter-
viewees’ views were largely consistent, with strong pat-
terns emerging during analysis. However, importantly,
almost two-thirds of our interviewees came from the
two largest Scottish health boards. Moreover, not all
professionals approached agreed to take part in an inter-
view. Though interviewees’ statements regarding their
peers and the culture of their specialty suggest that ac-
counts are reflective of a wider, prevailing view, this is
not something of which we can be entirely sure. It is
possible our sample is skewed towards more research-
engaged clinicians; the perspective of those not
approached or declining involvement might be different,
with the latter perhaps not seeing our study as some-
thing to which they could usefully contribute. Also of
note is that a relatively small number of nurses were
interviewed. Though differences in perspective could not
be discerned in our data, future research might usefully
explore the perspectives of this staff group in more
depth. Looking beyond oncology, Cambrosio et al. [40]
advocate caution in extrapolating between specialties
and indeed suggest that oncology may be distinctive. We
have already highlighted a number of ways in which the
trial work the interviewees were engaged in appeared
idiosyncratic. We note here, however, that work on trials
in other clinical areas, for example, diabetes, has identi-
fied similar concerns about financial pressures and
difficulties undertaking less profitable studies [16]. Fi-
nally, as to whether our findings have relevance beyond
the country and health service context in which the re-
search was undertaken, this question hinges on the com-
parability of service organisation and resourcing. We
would encourage readers with direct experience of other
healthcare systems to think critically about and explore
further the application of our findings to those contexts.
Further research may be warranted.
Conclusions
Accounts revealed growing tensions between the ethos of
the clinician–researcher, who delivers the best care through
the vehicle of trials, and the need to make pragmatic eco-
nomic choices which inevitably diminish some patient
groups’ access to such care. The utilitarian logic underpin-
ning professionals’ decision-making about engagement in
trials was recognised by some interviewees as having conse-
quences for equality of care, in particular, placing patients
such as TYA, who typically present with rare types of can-
cer, and/or who are served by smaller treatment centres, at
a disadvantage. The consequences of inequality in access to
trials were not explicitly explored in this study. However,
denial of those benefits associated by interviewees with trial
participation might reasonably be inferred. Moreover, prior
research suggests that interviewees’ discomfort with the
situation has strong foundations. For example, scrutiny of
outcomes in TYA cancer patients has indicated that rates
of clinical trial participation and improvements in survival
(or lack of these) are closely associated [3, 4]. In the United
States, ‘inclusion in research has come to be seen as an im-
portant strategy for reducing health disparities’ (p.338) [54],
with recognition of inequalities in access to trials along lines
of race and gender prompting legislation to promote the in-
volvement of what were subsequently deemed ‘special pop-
ulations’ [1]. We do not go so far as to suggest that such an
approach be taken here, but argue that at the very least a
far franker debate is needed if the issues our study high-
lights can begin to be resolved.
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